Business Description
Savara Inc
NAICS : 325412
SIC : 2834
ISIN : US8051111016
Description
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.22 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.13 | |||||
| Debt-to-EBITDA | -0.3 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 23.6 | |||||
| 3-Year EPS without NRI Growth Rate | 26.9 | |||||
| 3-Year FCF Growth Rate | 24.7 | |||||
| 3-Year Book Growth Rate | -5.1 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.22 | |||||
| 9-Day RSI | 48.98 | |||||
| 14-Day RSI | 48.04 | |||||
| 6-1 Month Momentum % | -9.66 | |||||
| 12-1 Month Momentum % | -28.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 17.7 | |||||
| Quick Ratio | 17.7 | |||||
| Cash Ratio | 17.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -36.6 | |||||
| Shareholder Yield % | 0.14 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -58.42 | |||||
| ROA % | -46.26 | |||||
| ROIC % | -612.93 | |||||
| ROC (Joel Greenblatt) % | -35915.52 | |||||
| ROCE % | -52.7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.81 | |||||
| Price-to-Tangible-Book | 2.97 | |||||
| EV-to-EBIT | -4.17 | |||||
| EV-to-Forward-EBIT | -3.51 | |||||
| EV-to-EBITDA | -4.18 | |||||
| EV-to-Forward-Revenue | 93.72 | |||||
| EV-to-FCF | -4.54 | |||||
| Price-to-Net-Current-Asset-Value | 3 | |||||
| Price-to-Net-Cash | 3.12 | |||||
| Earnings Yield (Greenblatt) % | -23.98 | |||||
| FCF Yield % | -14.47 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Savara Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.384 | ||
| Beta | 0.41 | ||
| Volatility % | 34.71 | ||
| 14-Day RSI | 48.04 | ||
| 14-Day ATR (€) | 0.099468 | ||
| 20-Day SMA (€) | 3.173 | ||
| 12-1 Month Momentum % | -28.05 | ||
| 52-Week Range (€) | 2.72 - 5.05 | ||
| Shares Outstanding (Mil) | 171.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Savara Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Savara Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Savara Inc Frequently Asked Questions
What is Savara Inc(FRA:YB4P)'s stock price today?
The current price of FRA:YB4P is €3.06. The 52 week high of FRA:YB4P is €5.05 and 52 week low is €2.72.
When is next earnings date of Savara Inc(FRA:YB4P)?
The next earnings date of Savara Inc(FRA:YB4P) is 2025-03-07 Est..
Does Savara Inc(FRA:YB4P) pay dividends? If so, how much?
Savara Inc(FRA:YB4P) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers